Silence Therapeutics PLC | Ownership
Companies that own Silence Therapeutics PLC
Invesco Asset Management Ltd.
8,281,131
11.82%
-52,202
0.02%
12/31/2017
Aviva Investors Global Services Ltd.
3,594,883
5.13%
-97,723
0.01%
12/31/2017
Woodford Investment Management Ltd.
3,424,047
4.88%
-68,535
0.04%
12/31/2017
Lombard Odier Asset Management (Europe) Ltd.
2,385,694
3.41%
-1,109,683
0.09%
12/31/2017
NNIP Advisors BV
1,719,843
2.45%
-1,823,666
0.01%
08/24/2018
Henderson Global Investors Ltd.
1,534,000
2.19%
0
0%
06/04/2018
NFU Mutual Investment Services Ltd.
917,000
1.31%
0
0.03%
06/04/2018
HSBC Bank Plc (Market-Maker)
628,000
0.9%
25,000
0.2%
06/04/2018
Polar Capital LLP
583,000
0.83%
0
0%
06/04/2018
Hargreaves Lansdown Asset Management Ltd.
293,000
0.42%
9,000
0.01%
06/04/2018
| Address |
72 Hammersmith Road
London Greater London W14 8TH
United Kingdom
|
|
Employees
|
- |
| Website |
http://silence-therapeutics.com |
| Updated |
07/08/2019 |
| Silence Therapeutics Plc engages in the development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. |
